# Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

> **NCT05513573** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Henlius Biotech** · enrollment: 75 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma by AJCC V8 Stage

## Interventions

- **DRUG:** HLX07
- **DRUG:** HLX10
- **DRUG:** placebo
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT05513573
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-14
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513573, "Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05513573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*